Questions about inhaled beta 2-adrenoceptor agonists in asthma

Trends Pharmacol Sci. 1992 Jan;13(1):20-3. doi: 10.1016/0165-6147(92)90011-t.


The safety of the most widely prescribed antiasthma drugs, beta 2-adrenoceptor agonists, has recently been questioned. Issues such as their suitability for long-term and regular prophylactic use are addressed in this Comment article by Peter Barnes and Fan Chung, who examine the possibility that the beta 2-agonists themselves contribute to worsening symptoms in asthma patients, thus setting up a vicious circle with greater use of the drugs. They conclude that it would be prudent to restrict the use of beta 2-agonists in asthma to on-demand immediate symptom control.

Publication types

  • Review

MeSH terms

  • Administration, Inhalation
  • Adrenergic beta-Agonists / administration & dosage*
  • Adrenergic beta-Agonists / adverse effects
  • Asthma / drug therapy*
  • Asthma / mortality
  • Humans


  • Adrenergic beta-Agonists